Rarity Bioscience provides ultra-sensitive multiplex assays for mutation detection in blood and other liquid biopsies for research, pharma and labs.
The superRCA technology is based on padlock probes and rolling circle amplification, enabling extreme sensitivity and specificity, and utilize well established high throughput flow cytometry for the read-out.
The company was founded in 2021 based on a discovery by Dr Lei Chen, PhD in molecular biology, and a member of Professor Ulf Landegrens team at the Department of Immunology, Genomics and Pathology at Uppsala University.
Company Details
- Employees
- 22
- Founded
- -
- Address
- Dag Hammarskjölds Väg 56e, Uppsala,uppsala County 752 37,sweden
- Industry
- Biotechnology
- Website
- http://www.raritybioscience.com
- Keywords
- Mutation detection, MRD, Liquid biopsy, In vitro diagnostics, Oncology, Cancer research, Relapse Monitoring, Cancer diagnostics, Flowcytometry, PCR, superRCA, mutation testing in blood and bone marrow, Leukemia, Molecular MRD, Clinical Flow Cytometry, Molecular diagnostics, Laboratory services, Flow Cytometry, Sample mutation analysis, cfDNA, ctDNA.
- HQ
- Uppsala, Uppsala County
Rarity Bioscience Questions
Rarity Bioscience's website is http://www.raritybioscience.com
Rarity Bioscience's LinkedIn profile is https://se.linkedin.com/company/rarity-bioscience
Rarity Bioscience has
22 employees.
View email and phone details for 22
employees at Rarity Bioscience.
Rarity Bioscience's industry is
Biotechnology
Rarity Bioscience's top competitors are
Readily Diagnostics,
Bioarctic,
Moleculent,
Phenaros,
Pixelgen Technologies,
Olink Proteomics,
Strike Pharma Ab,
Biolamina,
Pelago Bioscience Ab,
Navinci.
Rarity Bioscience's categories are Biotechnology
Rarity Bioscience's founding year is 2021
